Wednesday, June 20, 2018 New results from the groundbreaking “Trial Assigning Individualized Options for Treatment Rx” (TAILORx) breast cancer trial (CCTG MAC.12 in Canada), show no benefit from chemotherapy for 70% of women with the most common form of breast cancer. The study found that for a group of women with hormone receptor (HR)-positive, HER2 negative, axillary lymph node-negative breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more beneficial than with hormone therapy alone. These results were presented at the American Society of Clinical Oncology (ASCO) annual meeting on June 3, 2018 and simultaneously published in the New England Journal of Medicine. Publication Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (ONLINE). N Engl J Med 2018. https://www.nejm.org/doi/full/10.1056/NEJMoa1804710?query=featured_home For more information:https://www.ctg.queensu.ca/cctg_news/tailorx-mac12-trial-showed-no-benefit-chemotherapy-women-breast-cancer
